Cargando…
Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial
CONTEXT: Long-acting recombinant human growth hormone (rhGH) has transformed growth hormone deficiency (GHD) treatment. However, the possibility and rationality for flexible time regimen are pending. OBJECTIVE: We studied the efficacy of biweekly versus weekly PEGylated rhGH (PEG-rhGH) therapy in GH...
Autores principales: | Sun, Chengjun, Lu, Biao, Liu, Yu, Zhang, Yaqin, Wei, Haiyan, Hu, Xu, Hu, Pei, Zhao, Qian, Liu, Yanling, Ye, Kan, Wang, Kan, Gu, Zaiyan, Liu, Zheng, Ye, Jin, Zhang, Hongxiao, Zhu, Hong, Jiang, Zhihong, Liu, Yanjie, Wan, Naijun, Yan, Chengming, Yin, Jianying, Ying, Lirong, Huang, Feng, Yin, Qingjin, Xi, Li, Luo, Feihong, Cheng, Ruoqian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655095/ https://www.ncbi.nlm.nih.gov/pubmed/34899612 http://dx.doi.org/10.3389/fendo.2021.779365 |
Ejemplares similares
-
Corrigendum: Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial
por: Sun, Chengjun, et al.
Publicado: (2021) -
Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children
por: Hou, Ling, et al.
Publicado: (2015) -
Long-term Pegylated GH for Children With GH Deficiency: A Large, Prospective, Real-world Study
por: Hou, Ling, et al.
Publicado: (2023) -
Novel aggrecan variant, p. Gln2364Pro, causes severe familial nonsyndromic adult short stature and poor growth hormone response in Chinese children
por: Xu, Dandan, et al.
Publicado: (2018) -
PEGylated Recombinant Human Growth Hormone Jintrolong(®) Exhibits Good Long-Term Safety in Cynomolgus Monkeys and Human Pediatric Growth Hormone Deficiency Patients
por: Wu, Wei, et al.
Publicado: (2022)